These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24496699)

  • 1. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Cardenas P; Hester A; Brunel P; Zhang J
    BMJ Open; 2014 Feb; 4(2):e004254. PubMed ID: 24496699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
    Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
    Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
    Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
    Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
    Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
    Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
    Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
    J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
    Ito S; Satoh M; Tamaki Y; Gotou H; Charney A; Okino N; Akahori M; Zhang J
    Hypertens Res; 2015 Apr; 38(4):269-75. PubMed ID: 25693859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension.
    Wang X; Song F; Jiang L; Huang Z; Luo S; Li X; He X
    Am J Hypertens; 2024 Jul; 37(8):612-620. PubMed ID: 38564196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
    Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
    Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.
    Kario K; Tamaki Y; Okino N; Gotou H; Zhu M; Zhang J
    J Clin Hypertens (Greenwich); 2016 Apr; 18(4):308-14. PubMed ID: 26402918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
    Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
    J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
    Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.
    Hayoz D; Zappe DH; Meyer MA; Baek I; Kandra A; Joly MP; Mazzolai L; Haesler E; Periard D
    J Clin Hypertens (Greenwich); 2012 Nov; 14(11):773-8. PubMed ID: 23126349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.